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Abstract
Background: The Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) is a multidimensional outcome
measure designed to capture, evaluate and discriminate pain from neuropathic and non-neuropathic sources. A
recent systematic review found insufficient psychometric data with respect to musculoskeletal (MSK) health conditions. This study aimed to describe the reproducibility (test–retest reliability and agreement) and internal consistency
of the SF-MPQ-2 for use among patients with musculoskeletal shoulder pain.
Methods: Eligible patients with shoulder pain from MSK sources completed the SF-MPQ-2: at baseline (n = 195), and
a subset did so again after 3–7 days (n = 48), if their response to the Global Rating of Change (GROC) scale remained
unchanged. Cronbach alpha (α) and intraclass correlation coefficient (ICC2,1), and their related 95% CI were calculated.
Standard error of measurement (SEM), group and individual minimal detectable change (MDC90), and Bland–Altman
(BA) plots were used to assess agreement.
Results: Cronbach α ranged from 0.83 to 0.95 suggesting very satisfactory internal consistency across the SF-MPQ-2
domains. Excellent ICC2,1 scores were found in support of the total scale (0.95) and continuous subscale (0.92) scores;
the remaining subscales displayed good ICC2,1 scores (0.78–0.88). Bland–Altman analysis revealed no systematic bias
between the test and retest scores (mean difference = 0.13–0.19). While the best agreement coefficients were seen on
the total scale (SEM = 0.5; MDC90individual = 1.2 and M
 DC90group = 0.3), they were acceptable for the SF-MPQ-2 subscales
(SEM: range 0.7–1; M
 DC90individual: range 1.7–2.3; MDC90group: range 0.4–0.5).
Conclusion: Good reproducibility supports the SF-MPQ-2 domains for augmented or independent use in MSKrelated shoulder pain assessment, with the total scale displaying the best reproducibility coefficients. Additional
research on the validity and responsiveness of the SF-MPQ-2 is still required in this population.
Keywords: Reproducibility, Reliability, Agreement, McGill pain questionnaire, Shoulder pain, Musculoskeletal
conditions, Patient-reported outcomes, Psychometric properties
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Background
Shoulder disorders are among the three leading causes of
musculoskeletal (MSK) pain, third only to neck pain and
low back pain [1, 2]. The prevalence of shoulder disorders
increases with aging [3, 4]. Shoulder disorders are associated with substantial consequences for the socioeconomic wellbeing of the patient and society; studies have
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linked workers’ absenteeism, job loss, and poor healthrelated quality of life (HRQoL) to symptoms associated
with shoulder disorders [3, 5–8].
Pain assessment in clinical practice and research often
places emphasis on monitoring pain intensity, even
though pain is known to be multidimensional and experienced uniquely by individuals [9]. Patients perceive
pain across six diverse dimensions: physiologic, sensory,
affective, cognitive, behavioral and socio-cultural [9, 10].
The comprehensive assessment and monitoring of these
dimensions should improve patient care [11]. A multidimensional pain assessment tool that provides a holistic
assessment of pain has been recommended by experts
[12–14] for use in upper extremity conditions, including
shoulder disorders.
The Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) is an example of a general use multidimensional pain tool that comprehensively examines the
sensory and affective dimensions of pain. Dworkin et al.
[15] created the SF-MPQ-2 by adding seven new items
that explicitly examines neuropathic and non-neuropathic pain characteristics to the original 15-item Short
McGill Pain Questionnaire (SF-MPQ). They also replaced
the previous 4-point descriptive rating scale with a
10-item numerical rating scale to enhance its responsiveness [15]. Since then, multiple studies have utilized
the SF-MPQ-2 as a primary outcome for pain assessment in clinical trials; its measurement properties have
been examined in different populations including cancer
pain [16], surgical pain [17], visceral pain [18], and neuropathic pain [19]. Among MSK conditions, studies have
reported measurement evidence for patients with complex regional pain syndrome [20], back pain [21], knee
osteoarthritis (OA) [22], and mixed MSK populations
[23, 24]. Although the SF-MPQ-2 is becoming increasingly popular, our recent review [25–27] reported on evidence with design flaws including inadequate description
of Intraclass correlation coefficient (ICC) models, insufficient justification of retest interval, and a lack of attention to absolute reliability parameters.
In the absence of such evidence, the primary purpose
of this study was to investigate the reproducibility (test–
retest reliability and agreement) and internal consistency
of the Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) among persons with MSK-related
shoulder disorders.

Methods
This study was based on a cross-sectional study of internal consistency and test–retest reliability. The SF-MPQ-2
questionnaire was administered to examine reproducibility (test–retest reliability and agreement) and internal consistency at two time points: at baseline and after
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3–7 days (when patients would, for the most part, be
stable) [28, 29]. The participants were recruited from the
Roth-McFarlane Hand and Upper Limb Centre (HULC),
London, Ontario, Canada during a period of 6-months
(June to November 2018). Ethics approval for a clinical
database of routine outcome measures from which this
data were extracted was approved by the University of
Western Ontario Research Ethics Board (REB# 4986).
Patients

Adults proficient in English, above 18 years of age, that
experienced pain from one or more shoulder conditions
of known MSK source (for example: rotator cuff tear or
tendinopathy, adhesive capsulitis, glenohumeral anterior
instability, and superior labral anterior–posterior (SLAP)
lesions) were included. Potential participants were
excluded if they had: (1) an unstable cardiorespiratory
condition; (2) any history of problems relating with the
central nervous system e.g. hemiplegia; (3) pain resulting from neoplastic or infectious or vascular disorders or
referred from internal organs; (4) any neuropathic pain
symptoms resulting from thoracic outlet syndrome, carpal tunnel syndrome or any peripheral nerve entrapment,
or (5) did not provide consent.
Procedure

Assessors (SJ and HULC research assistants) identified
eligible participants by reviewing the outpatient appointment list of patients scheduled for a clinical visit with
two shoulder surgeons (KF and GA), a day prior. Potential participants were then contacted on the day of their
clinical appointment and screened to ensure all criteria
were satisfied; they were provided with an explanation of
the objectives of the study before a questionnaire booklet
containing the SF-MPQ-2 and Global Rating of Pain Scale
(GROC) was administered. Each participant was verbally
instructed to carefully read and circle the response that
described their pain experience. In cases where participants had difficulty with selecting an answer, they were
told to choose the answer that comes closest to describing their pain symptoms. If help was needed with understanding any words or phrases, or with marking their
responses, the assessors assisted. The participants were
instructed to complete all items in the questionnaire.
Participants were permitted to withdraw from the study
for any reason at any time. For the second test occasion,
a subset of the participants (102 in total) that verbally
confirmed being in unchanged/stable pain in the past
7-days were conveniently sampled to self-complete the
SF-MPQ-2 and GROC at home within 3–7 days, if their
pain remained unchanged (i.e. if they could confirm that
the threshold of their perceived pain for their shoulder
disorder had not changed in the past week). The GROC
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scale was administered, intentionally, on both test occasions solely to serve as an objective means of comparing
participants test and retest responses thus ensuring that
only participants in stable/unchanged pain conditions
were included in our analysis of reproducibility (test–
retest reliability and agreement). Demographic information including age, hand dominance, primary cause of
shoulder pain and sex were recorded.

occurring at the magnitude of 15% were considered substantial [30].

Outcome measure

Cross sectional reliability (internal consistency)

The Revised Short McGill Pain Questionnaire Version-2
(SF-MPQ-2) contains 22-items/pain descriptors and 4
subscales/domains that examine pain intensity and quality as follows: (1) continuous pain (throbbing, cramping,
gnawing, aching, heavy, and tender pain); (2) intermittent pain (shooting, stabbing, sharp pain, splitting pain,
electric-shock, and piercing pain); (3) neuropathic pain
(hot-burning, cold-freezing, pain caused by light touch,
itching, tingling or pins and needles, and numbness
pain), and (4) affective pain (tiring-exhausting, sickening,
fearful, and punishing-cruel). All the items are bounded
on a zero (none) to 10 (worst possible) numerical rating
scale. The mean of the 22-items yields the SF-MPQ-2
total score, while the mean of the items that comprise
each of four-subscales yields the summary score for the
subscale [15, 21]. Higher subscale or total scores suggest greater pain symptoms/experience, and more than
2 missing values renders patients’ response to the questionnaire invalid [21]. The SF-MPQ-2 uses a recall period
of 7-days, instructing the person to base their rating on
their symptoms in the past week [15].
Statistical analyses

The SF-MPQ-2 total and subscale scores were considered
as interval variables. Data quality and screening, including the percentage of missing data, outliers, and presence
of floor/ceiling effects was performed. Respondents with
two or more missing items were excluded, in line with the
developers’ instructions [21]. Continuous variables were
descriptively summarized using means and standard
deviations while percentages were used to report categorical variables. The data were then examined for normality with histograms, and the Shapiro–Wilk test. All
statistical analyses were completed with Microsoft Excel
Version 2013 and SPSS statistic for Windows™, Version
25.0. (Armonk, NY: IBM Corp, Released 2017).
Floor/ceiling effects

Floor/ceiling effects for the SF-MPQ-2 were assessed by
identifying the number of participants with the absolute
lowest (0-points = floor) and highest (10-points = ceiling)
scores on the total and subscales. Floor/ceiling effects

Hypothesis: We expected substantial floor effects on
the neuropathic and affective subscales of the SF-MPQ-2
because they evaluate pain dimensions that are relatively
uncommon in orthopaedic shoulder disorders.

Internal consistency, the degree of item inter-relatedness/equivalence in a Patient-Reported Outcome Measure (PROM) [30–32], was assessed with Cronbach alpha
(α) and associated 95% confidence intervals. An α ≥ 0.7 is
a commonly accepted standard for internal consistency
reliability. However, redundancy is suggested at α > 0.95
[30, 32, 33].
Hypothesis: We expected the SF-MPQ-2 to be internally consistent with Cronbach α at 0.8 or above for its
subscale scores, and 0.9 or above for its total scores as
previously reported in the literature [22, 24].
Relative reliability (test–retest reliability)

The intraclass correlation coefficient (ICC2,1) was used
to assess the retest reliability of the SF-MPQ-2 total and
subscales [34]. ICC2, 1 with 95% confidence intervals (CI)
were computed using the two-way mixed and absolute
agreement model, that assumes the patients were randomly selected but the occasions were fixed choices [35].
We chose an ICC2,1 absolute agreement over a consistency model because it captures elements of systematic
bias and is preferred for computing an absolute reliability
indicator. ICC2,1 values for the SF-MPQ-2 total and subscale scores were considered Negative ≤ 0.49, Doubtful
0.50–0.69, Good 0.70–0.89, and Excellent 0.90–1.00 [36].
Hypothesis: We expected good ICC2,1 scores for group
level analysis at ≥ 0.80 for the total scale and ≥ 0.70 for
the subscale scores as previously reported in the literature [22, 24].
Agreement properties (standard error of measurement [SEM]
and minimal detectable change [MDC])

Standard error of measurement (SEM) is defined as
the standard deviation of errors of measurement associated with particular test takers’ scores [37]. Table 1
explains the five equations used for agreement analysis. To define 
SEMagreement for the SF-MPQ-2 total
and subscales scores, the pooled standard deviation calculated from participants’ mean responses to
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Table 1 Summary of equations used in agreement analysis
Equation Formula

Purpose

1

SDpooled = (SDtest + SDretest)/2

For estimating pooled standard deviation (SDpooled) from the test and retest scores.
The SDpooled is among the indices required for SEMagreement estimation

2

√
SEMagreement = Standard Deviationpooled × 1 − ICC 2,1 For estimating S EMagreement, which is important for the MDC90individual estimation
MDC90individual = 1.64 × √2 × SEMagreement

For determining the point estimate of MDC90individual, which is required for estimating the confidence interval range and the MDC90group scores per subscale of the
SF-MPQ-2

4

95% CI for MDC90individual = d ± MDC90individual

For computing the 90% confidence interval range for the MDC90individual score
obtained for each subscale of SF-MPQ-2

5

MDC90group = MDC90individual /√n × 1.64

For estimating the M
 DC90 group score for the entire population

3

SEMagreement standard error of measurement (agreement), SDtest standard deviation of test scores, SDretest standard deviation of retest scores, SDpooled pooled standard
deviation, n sample size, CI confidence interval, MDC90individual individual level minimal detectable change at 90% CI, MDC90group group level minimal detectable change
at 90% CI, d mean difference, ICC2,1 intraclass correlation coefficient

the SF-MPQ-2 domains on both test and retest using
Eq. 1 [37, 38] and the respective non-transformed
ICC2,1 for the SF-MPQ-2 domain under evaluation was keyed into Eq. 2 [37–39] (Table 1). Further,
the proportion of the resulting SEM per domain to
the total score of the scale was calculated to yield
the SEM percentage or SEM%, as previously used
[39–41] and interpreted as follows: ≤ 5% = very
good; > 5–≤ 10% = good; > 10–< 20% = doubtful;
and
values above 20% = negative [39].
The minimal detectable change (MDC) or repeatability coefficient describes the minimum amount of change
that must occur on a score to be confident that true/real
change (that may or may not be clinically significant)
has occurred without error after two repeated measures, within the period of the test–retest [42]. For this
study, a 90% confidence interval was estimated for the
Minimal Detectable Change (MDC90). Like the SEM, it
is also expressed in the unit of the measure and may be
computed at an individual level (MDC90individual) or for a
group (MDC90group) [29]. We estimated M
 DC90individual for
the total and subscale scores of the SF-MPQ-2 by entering each scale’s S
 EMagreement into Eq. 3 (Table 1) assuming
the data was normally distributed and free of systematic
error. The M
 DC90individual confidence interval was then
computed from the mean differences (d) of each subscale
using Eq. 4 (Table 1) [29, 40, 43].
To determine the group level minimal detectable
change (MDC90group), which is useful for determining
if changes have occurred in an entire population, Eq. 5
(Table 1), the formula proposed by de Vet et al. [30, 44]
was employed. The proportion of the resulting MDC
coefficient per SF-MPQ-2 domain to the total score
of the scale was computed to yield the MDC percent
score (MDC%) and interpreted as follows: ≤ 5% = very
good; > 5–≤ 10% = good; > 10–< 20% = doubtful;
and
values above 20% = negative [39, 40].

Bland–Altman Plots (BA Plots)

The Bland–Altman (BA) method was used to visually examine the agreement between the test and retest
scores [45, 46]. Scatter plots were created to demonstrate the differences between the total and subscale
scores obtained at time one and time two of the test–
retest interval against their mean score for the two time
points [45–48]. We then calculated the mean difference
between the two measurement intervals (the ‘bias’) and
the 95% limits of agreement (LoA) using: LoA = mean
difference (d) ± 1.96 SD of the mean differences. The BA
plots were used to visually judge the 95% limits of agreement to determine how well the scores from repeated
measurements agreed: narrower LoAs suggested better
agreement at the individual level [29, 47, 49]. Agreement
at the group level was determined by how close the bias
(mean difference) was to zero. Also, the distribution of
scatter points on the BA plots were visually scrutinized
for evidence of variability or heteroscedasticity, where
the absence of a linear relationship between test–retest
mean differences and their mean scores, per subscale,
suggest the absence of systematic bias [44–48, 50]. Linear
regression models were used to explore the presence of
systematic bias. For each domain of the SF-MPQ-2, mean
scores and differences in mean scores were modelled as
the independent and dependent variables, respectively.
The potential for systematic bias was appraised by checking if the prediction of the differences in the mean scores
was statistically significant [47, 51]. Finally, outliers that
presented beyond the upper and lower boundaries of the
LoA were noted and explored [29, 52].

Results
Figure 1 below summarizes the flow of participants
through the different phases of the study. Of the 238
eligible patients identified from the review of the surgeons’ scheduled appointment list, 195 consenting adults

Jumbo et al. Health Qual Life Outcomes

(2020) 18:365

Page 5 of 12

Potential Participants Identified
from Surgeons’ Appointment
schedules and EMR Chart

(n = 238)

Participant that completed the
SF-MPQ-2 at baseline (Time 1)
(n=208)

Did not meet predefined inclusion
criteria:
1. Did not consent to participate (n= 10)
2. Not English speaking (n = 5)
3. Severe cardiovascular disorder (n = 4)
4. Inpatient booked for surgery (n=11)

Excluded due to missing data when
completing the SF-MPQ-2

(n = 13)

Participants for
Reproducibility Analysis
(n=195)

Participants offered
take-home retest
envelops

(n = 102)

Did not return
Time 2 envelops

(n = 45)
Retest envelops
returned

(n = 55)

Excluded due to
Missing data

(n = 7)

Included in
Cross-sectional reliability
(Internal consistency)
assessment

(n = 195)

Included in absolute
(SEM, MDC, BA plots)
and relative (ICC2,1)
reliability assessment

(n = 48)

Fig. 1 Flow chart of progress through the phases of screening, recruitment, test, retest and data analysis

satisfied the inclusion criteria and provided complete
data that were considered in our analysis of cross-sectional reliability. For the analysis of test–retest reliability and agreement, of the 102 participants that agreed
to participate in the second test occasion, only 48 out of

55 stable subjects provided a complete response to SFMPQ-2 in a mean of 4 days following the index test.
Table 2 summarizes the characteristic and demographic distribution of the baseline population. The study
population was equally comprised of males and females,
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Variables

N/%

Age in years (mean + SD)

(62 + 17) 195/100%

sample size was greater than 30 participants (based on
the central limit theorem). Despite that, we still examined
for differences in reproducibility coefficients obtained
using the transformed and non-transformed ICC scores.

Glenohumeral joint arthroplasty

39/20%

Floor and ceiling effects

Humeral and others fractures (i.e. clavicular, costal,
scapular)

23/12%

Rotator cuff pathologies

48/25%

Dislocation

12/6%

Osteoarthritis

18/9%

Impingement/bursitis

15/8%

Other (MSK pain-related/non-specific)

40/21%

The presence of floor/ceiling effect may suggest an outcome measure is not responsive to detecting improvement (ceiling effect) even though a decline in status can
be captured, and vice versa for floor effects [21]. The
number of patients who obtained the absolute maximum
(Ten, 10) and minimal (zero, 0) scores on the SF-MPQ-2
total and subscales are summarized in Table 3. The greatest level of floor effect was observed on the affective subscale at both periods of the test–retest. Substantial floor
effects were also noted on the neuropathic and intermittent subscales. None of the SF-MPQ-2 indices had
remarkable ceiling effects.

Table 2 Patient baseline characteristics (N = 195)

Shoulder disorders

Affected shoulder
Right

111/56%

Left

71/36%

Both

13/6%

Sex
Males

103/53%

Females

92/47%

Internal consistency (cross‑sectional reliability)

N number of patients, SD standard deviation

with a mean age of 62 years, with different shoulder disorders of various MSK pathologies including rotator
cuff injuries, humeral fracture and glenohumeral joint
arthroplasty.
Both the graphical and statistical tests of normality
revealed the dataset was skewed/abnormal. To address
the assumption of normality for further analysis, a
square root calculation was used to transform the data.
A closer look at the reliability coefficients obtained using
the transformed and untransformed data revealed only a
small difference in scores (see Table 3 for results). Parametric statistics were used in our analysis because the

Table 3 Floor and ceiling effects for test–retest scores
of the SF MPQ-2 total and subscale scores (N = 48)
Variables

Test

Retest

Table 4 summarizes the results obtained for cross sectional reliability. The SF-MPQ-2 displayed excellent
internal consistency with robust α coefficients within
a range that suggest the absence of redundancy: α coefficients for the total subscale peaked at 0.95 as posited,
while that for the subscales fluctuated between 0.83 and
0.86 points. Inter-item correlations were satisfactory,
ranging from 0.23–0.53 across the scales.
Agreement properties (absolute test–retest reliability)

Table 5 summarizes the agreement parameters supporting the SF-MPQ-2 domains. The total scale S
 EMagreement
was very low (0.51points) and approximately 5% of the
total score of the scale, which is ‘very good’ according to

Table 4 Cross-sectional reliability of the SF-MPQ-2 total
and subscale scores (N = 195)
Variables

Internal consistency (N = 195)
Cronbach alpha (95% CI)

Inter-item
correlation

SF-MPQ-2
Continuous

0.87 (0.84–0.90)

0.43–0.67

0/48 = 0%

SF-MPQ-2
Intermittent

0.87 (0.84–0.90)

0.42–0.77

20/48 = 42%

0/48 = 0%

SF-MPQ-2
Neuropathic

0.85 (0.81–0.88)

0.32–0.81

0/48 = 0%

11/48 = 23%

0/48 = 0%

SF-MPQ-2
Affective

0.83 (0.79–0.87)

0.44–0.78

0/48 = 0%

4/48 = 8%

0/48 = 0%

SF-MPQ-2
Total

0.95 (0.94–0.96)

0.21–0.78

Floor

Ceiling

Floor

Ceiling

SF-MPQ-2
Continuous

7/48 = 15%

0 /48 = 0%

4/48 = 8%

1/48 = 2%

SF-MPQ-2
Intermittent

11/48 = 23%

0/48 = 0%

15/48 = 31%

SF-MPQ-2
Affective

19/48 = 40%

1/48 = 2%

SF-MPQ-2
Neuropathic

14/48 = 29%

SF-MPQ-2
Total

3/48 = 6%

SF-MPQ-2 Revised Short McGill Pain Questionnaire Version-2, % proportion in
percentages

SF-MPQ-2 Revised Short McGill Pain Questionnaire Version-2, CI confidence
interval
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Table 5 Agreement parameters (absolute reliability) of the SF-MPQ-2 total and subscale scores (N = 48)
Variables

SEMagreement

SF-MPQ-2
Continuous

0.8

SF-MPQ-2
Neuropathic

SEM (%)

MDC90individual (95% CI)

MDC (%)

MDC90group

8

1.8 (− 1.6 to 2.0)

18

0.4

0.8

8

1.8 (− 1.7 to 1.9)

18

0.4

SF-MPQ-2
Intermittent

1.0

10

2.3 (− 2.1 to 2.4)

23

0.5

SF-MPQ-2
Affective

0.7

7

1.7 (− 1.5 to 1.8)

17

0.4

SF-MPQ-2
Total

0.5

5

1.2 (− 1.0 to 1.4)

12

0.3

SF-MPQ-2 Revised Short McGill Pain Questionnaire Version-2, CI confidence interval, SEM standard error measurement, MDC minimal detectable change
SEM (%) and MDC (%) is expressed as the proportion of the obtained SEMagreement or MDC90individual of domain represented on the SF-MPQ-2 to the total score of the
scale (i.e. 10 points)

our criteria. Individual subscale S
 EMagreement ranged from
0.73 to 0.99 (approximately ≤ 10% of the total score),
which is also ‘good’ according to our criteria. At the individual level, acceptable scores within 1.19–2.29 points
were seen in support of minimal detectable change
(MDC) at a 90% confidence level. Of all the SF-MPQ-2
domains, the total scale had the lowest MDC score at
1.20 points (i.e. 12%) while the intermittent subscale
had the most substantial MDC scores at 2.29 points (i.e.
23%). For Group MDC90, estimates were acceptable and
expectedly lower than those obtained for M
 DC90individual;
the results fluctuated within 0.28 (total) to 0.54 (intermittent) points across the SF-MPQ-2 domains (Table 5).
Relative test–retest reliability

The test–retest reliability of the SF-MPQ-2 domains
was rated “Good” to “Excellent” (Table 6). Our results
for ICC2,1 were based on an analysis conducted with the
non-transformed data, as they did not differ from that

obtained with transformed data. I CC2,1 scores were highest on the continuous and total subscales and rated excellent according to our criteria. The neuropathic, affective
and intermittent subscales displayed good ICC2,1 coefficients (Table 6) in support of relative reliability.
Bland–Altman (BA) analysis/plots

The results of our Bland–Altman analysis are presented
in Table 6. The Bland–Altman plots superimposed with
the LoA and mean difference (bias) scores for each
domain of the SF-MPQ-2 are graphically illustrated
(Fig. 2a–e).All of the SF-MPQ-2 domains displayed
acceptable LoA at a 95% confidence level with the highest distance ranging 5 points (intermittent subscale). The
total scale score displayed the narrowest LoA (range = 3
points), with the remaining subscales within satisfactory
limits. Mean difference scores (bias) were very acceptable
for all the SF-MPQ-2 domains (0.15–0.19 points).

Table 6 Relative reliability of the SF-MPQ-2 total and subscale Scores (N = 48)
Variables

Test–retest reliability
Test
Mean (SD)

Test
Mean (SD)

d (SD)

SF-MPQ-2
Continuous

2.8 (2.6)

2.7 (2.6)

0.19 (1.12)

− 0.14 to 0.51

− 2.01, 2.38

a

a

SF-MPQ-2
Intermittent

2.1 (2.3)

2.0 (2.4)

0.15 (1.39)

− 0.24 to 0.54

− 2.58, 2.88

a

a

SF-MPQ-2
Neuropathic

1.5 (1.6)

1.3 (1.7)

0.13 (1.10)

− 0.19 to 0.45

− 2.02, 2.28

a

a

SF-MPQ-2 Affective

1.5 (1.9)

1.3 (2.0)

0.15 (1.01)

− 0.14 to 0.45

− 1.83, 2.14

a

a

a

a

SF-MPQ-2 Total

2.0 (1.9)

1.9 (2.0)

95% CI of d

95% LoA

Single measure ICC2,1 (95% CI)
Transformed data

0.15 (0.73)

− 0.06 to 0.37

− 1.29, 1.59

0.90 (0.83–0.94)
0.82 (0.71–0.90)
0.78 (0.64–0.87)
0.85 (0.75–0.92)
0.92 (0.86–0.96)

Non-transformed data
0.91 (0.84–0.95)
0.82 (0.71–0.90)
0.78 (0.64–0.87)
0.87 (0.78–0.92)
0.93 (0.87–0.96)

SF-MPQ-2 Revised Short-form McGill Pain Questionnaire Version-2, d mean difference (test–retest), SD standard deviation, CI confidence interval, LoA limits of
agreement, ICC intraclass correlation coefficient
a

All correlation coefficient (r) were statistically significant at p < 0.001 (2-tailed)
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c

2.5
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Difference SF-MPQ-2 Total (Test-retest)

2
d+1.96SD = 1.59
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1
0.5
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0
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-2
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5
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2
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2

3
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d

4
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3

8

22

d+1.96SD = 2.28

2

24

1
d = 0.13

0
-1
-2

d-1.96SD = -2.02
32

-3
-4

4

5

6

7

8

1

2

3

4

5

6

3
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45

d+1.96SD = 2.38

2

1
d = 0.19

0

-1

-2

7

8

9

-3
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0

1

2

d-1.96SD = -2.01

3

Difference SF-MPQ-2 Affective (Test-retest)

4

5

6
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8

9
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Mean SF-MPQ-2 Continous (Test-retest)

Mean SF-MPQ-2 Neuropathic (Test-retest)

e

10

4
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0

9

Mean SF-MPQ-2 Intermittent (Test-retest)

Difference SF-MPQ-2 Continous (Test-retest)

Difference SF-MPQ-2 Neuropathic (Test-retest)

b

d-1.96SD = -2.58

2

3…

3
27

d+1.96SD = 2.14

2
1

d = 0.15

0
-1
-2

d-1.96SD = -1.83

-3
2

-4
-5

0

1

2

3
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9

10

Mean SF-MPQ-2 Affective (Test-retest)

Fig. 2 a–e The Bland–Altman Limits of Agreement (LoA) plots between the test and retest scores of the SF-MPQ-2 Total (a), Neuropathic (b),
Intermittent (c), Continuous (d) and Affective (e) subscale scores (n = 48). The difference between test–retest scores is plotted against the mean
of test and retest scores for the respective SF-MPQ-2 total and subscales depicted. On each plot, the central blue line represents the mean of intra
individual differences (d); the upper and lower horizontal broken lines represent the 95% LoA. The 95% LoA shows that 95% of the intra individual
differences are within ± 1.96 SD of the mean difference (d). The outlier noted in each BA plot is numbered, according to participant #RS I.D., and
presented in accordance with the SF-MPQ-2 subscale or total scores in which they were noted

Visual inspection of scatter points on the BA plots for
each domain of the SF-MPQ-2 revealed that the magnitude of the mean differences against the mean scores
were uniformly distributed from the zero point and
most scatter points were within the 95% LoA with the
exception of a few outliers. This supports the absence of

systematic bias and suggest a good level of agreement
among test–retest scores. Furthermore, for each of the
SF-MPQ-2 domains, there was no evidence of the mean
difference scores predicting the mean average after our
regression model analysis. These findings suggest that
systematic bias is unlikely and confirms good level of
agreement between the test–retest scores (Table 6).
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The few outliers noted were explored. First, we determined if they were erroneous responses in entry by
rechecking hard copies but, indeed, they were ‘interesting’ outliers [53] and labelled according to their #RS on
each BA plot. The greatest number of interesting outliers presented on the intermittent (n = 6, 12%) and neuropathic (n = 4, 10%) subscales. The least number of
outliers were seen on the affective subscale (n = 2, 4%). In
general, however, the presence of these outliers did not
indicate the presence or absence of bias [53].

Discussion
This study provides reproducibility evidence that supports the use of the SF-MPQ-2 in multidimensional
pain assessment of people with MSK shoulder pain. The
SF-MPQ-2 displayed good to excellent coefficients in
support of its relative reliability and absolute reliability
properties. The limits of agreement for the subscales and
total scores were very satisfactory.
The substantial floor effect observed on the neuropathic, intermittent and affective subscales can be
attributed to the robust discriminative properties of the
SF-MPQ-2 subscales and to the lower prevalence of these
problems in our study population. Conceptually, the SFMPQ-2 was expanded to provide a single tool that can
classify pain between neuropathic and non-neuropathic
sources [15, 21]. As outcome measures can be evaluative
or discriminative, combining both purposes within an
outcome measure is likely to result in these types of statistical issues. For instance, participants with pain emerging from neuropathic sources will be more inclined to
respond adequately to the neuropathic subscale, thereby
reducing the likelihood of floor effects. This has been
observed with the use of the SF-MPQ-2 among complex regional pain syndrome (CPRS) patients [20]. This
implies that floor effects on the SF-MPQ-2 domains may
not always represent redundancy, but rather, may suggest
that an item does not describe the patient’s pain experience [25].
Cross sectional reliability was established for the SFMPQ-2 total and subscale scores with satisfactory coefficients supporting internal consistency that are similar
to previous estimates among mixed-MSK[23] (total, 0.93;
subscale, 0.84–0.92), CRPS [20] (total, 0.95; neuropathic
subscale, 0.83), knee OA [22] (total, 0.88; subscale 0.75–
0.81) and acute back pain [21] (total, 0.93; subscale, 0.77–
0.84) patient populations. Inter-item correlations were
also adequate. The adequate Cronbach’s alpha obtained
signifies the absence of redundancy in the domains of SFMPQ-2 thus confirming their unidimensionality [32] to
capture the different pain characteristics they assess.
In the present study, ICC2,1 coefficients were good to
excellent for all the SF-MPQ-2 domain scores (total,
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0.93; subscales, 0.78–0.91), suggesting that they can
adequately discriminate among patients at the individual
level (total and continuous scale) and at the group level
(all of the SF-MPQ-2 domains) [29, 54]. These results
are comparable or better than previous findings reporting estimates among knee OA [22] (total scale, 0.90; subscales, 0.73–0.90) and mixed MSK patients [24, 55] (total
scale, 0.90–0.94; subscales, 0.73–0.90). Although acceptable, the lower performance of the neuropathic subscale
(0.78), with an ICC score that overlapped the ‘moderate’ confidence interval threshold (0.64–0.87), suggests
greater variability on this subscale, which makes it more
difficult to achieve a high ICC2,1 score.
Absolute reliability estimates allow clinicians to assess
true change in a patient in comparison to change that
might be expected from measurement error [30, 44].
Currently, no previous data have examined absolute reliability indices for the SF-MPQ-2 scores in any population. This makes direct interpretation and comparison
difficult; however, our use of the Ostelo et al. [39] definition of SEM and MDC by percentages allows comparison across the domains of the SF-MPQ-2, and with its
former version (SF-MPQ). The SEM for the total score
(≤ 5% of total scale score) was ‘very good’ and comparable to that reported for the former version (SF-MPQ)
among OA patients (≤ 3.64%) [56], but better than those
seen among mixed MSK patients assessed with the Norwegian version of the SF-MPQ (≤ 10%) [41]. Although
not as favorable as estimates noted on the total scale,
the affective and intermittent/continuous subscales had
‘good’ SEM coefficients (< 10%), which were comparable
to findings reported with the sensory subscale of the former SF-MPQ version among OA patients (< 10%) [56],
and superior to that reported in a mixed MSK population (< 14%) [41]. Basically, SEM estimates for all the
SF-MPQ-2 subscales were satisfactory and suggest an
adequate evaluative capacity that can yield scores less
prone to error when utilized by researchers/clinicians for
MSK shoulder pain assessment over time.
The MDC scores represent the minimal change in
scores after repeated administration that clinicians/
researchers can interpret as not due to chance variation for an individual or group in a population [42].
The MDC90indivdiual scores obtained for the SF-MPQ-2
domains implies that change at a magnitude equal or
greater than 1.8 (neuropathic), 1.7 (affective), 1.8 (continuous), 2.3 (intermittent), 1.2 (total) points represents
genuine improvement beyond chance with 90% confidence. The MDC scores for the total scale (≤ 12% of
the total score of the scale) were comparable to previous studies with the former version (SF-MPQ) among
OA patients (≤ 11.5%) and better than the results seen
among mixed MSK patients (≤ 26.4% of total score). For
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the MDC90group scores, the results obtained for the SFMPQ-2 domains imply that a change of at least 0.4 (affective), 0.5 (intermittent), 0.3 (total), 0.4 (neuropathic), 0.4
(continuous) points must be observed in a group to be
90% confident that this was change beyond random or
systematic error. In general, minimal detectable change
scores are useful when interventions are administered; to
be sure the intervention is effective, it must demonstrate
change beyond the MDC score reported for the scale.
Also, MDC90group indices can be used for sample size estimation in a randomized controlled trial, as they determine the number of participants that will be needed to
detect a change in the measure beyond error for a group,
if the Minimal Clinically Important Difference (MCID)
score for the population is unknown.
The Bland–Altman plots revealed satisfactory limits of agreement in support of the SF-MPQ-2 subscales.
However, the interpretation of how far apart two measurements can be before they are no longer considered
interchangeable depends on the contextual application
[47]. The limits of agreement between the test–retest of
the SF-MPQ-2 domains were reasonably smaller than
those seen in previous studies of its former version (SFMPQ) [41, 56], suggesting there is less variation between
the test and the retest of the SF-MPQ-2 [50]. Furthermore, no bias was found in the measurements between
the test–retest, as the inter-occasion mean difference was
minimal. This suggests that learning or test accommodation are not issues with using the SF-MPQ-2; moreover, our compliance to recommended time intervals
(3–7 days) [28, 29, 57] may have favored the agreement
outcomes. The intermittent subscale had the greatest
number of outliers of all the Bland–Altman plots (12%)
and may be due to the volatile nature of the pain descriptors comprising the scale.
The SF-MPQ-2 total scores displayed the best reproducibility parameters in support of its relative, absolute
and level of agreement parameters. This could be from
the number of items contained in the scale. For instance,
better ICC scores can be expected when variability is low.
Variability decreases when a greater number of descriptors comprise a scale, in comparison to those with fewer
descriptors [29]. As all 22 items of the SF-MPQ-2 contribute to the summary total scale scores, it is possible
this favors reproducibility.

conflict with the COSMIN recommendation, our sample size calculation suggested at least 46 patients were
required (see Appendix 1), which indicates our study
was adequately powered. Second, the patient population were from a single tertiary referral practice and our
findings may not be generalizable to a different context.
Third, since participants completed the retest (Time 2)
at home, we were unable to clarify instructions. However, independent completion is a requirement for routine administration. Further, the high level of agreement
between scores of the tests and the absence of systematic
bias suggest this was not a problem. Fourth, sample mean
age was 62 (± 17) years, which may not adequately reflect
the reliability of younger populations although shoulder
pathology prevalence increases with age. Finally, we did
not determine minimal clinically important difference.

Study limitations

Availability of data and materials
This study data set is not assessible to the general public. However, the analysis of the dataset is assessible on reasonable request to the corresponding
author, Samuel U. Jumbo.

While the present study findings provide preliminary evidence supporting the reproducibility of the SF-MPQ-2
for use in patients with shoulder disorders, it has several
limitations. First, the study sample size (48 participants)
was just under 50 participants which has been suggested
as a benchmark by the COSMIN [58, 59]. However, in

Conclusion
We conclude that the SF-MPQ-2 is satisfactorily internally consistent and provides good to excellent reproducibility coefficients (test–retest reliability and agreement)
for multidimensional pain assessment among patients
with musculoskeletal shoulder pain conditions. The total
scale displays the best reproducibility coefficients. Additional research on the validity and responsiveness of the
SF-MPQ-2 is still required in this population.
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Appendix 1: Formula used for sample size
calculation

n =2+

0.5k(Zα + Zβ )2
δ 2 (k − 1)

where:
• k = number of occasions = 2
• Zα represents the Z-value associated with the α value
of interest. Therefore, Z-value (1-tailed) for 0.05 is
equivalent to 1.645
• Zβ represents the Z-value associated with a Type
II error. At power 80%, β equals 0.20, and Z-value
(1-tailed) equals 0.842.
• δ = R value of Z transformed expected hypothesis
minus R value of Z transformed null hypothesis, i.e.
δ = Z Rexpected – Z Rnull
Where
Z Rexpected = reliability value expected from analysis
Rexpected = 0.9
Z Rnull = lower confidence limit for the desired confidence interval width
1+(k−1)R
• ZRexpected = 0.5 natural log 1−R expected
expected

= 1.47
• ZRexpected = 0.5 natural log 1+(2−1)0.9
1−0.9
lowerlimit
• ZRnull = 0.5 natural log 1+(2−1)R
1−Rlowerlimit
• Rlowerlimit = 0.09—0.10 = 0.80 (at 0.10 Confidence Interval width)
• Z Rnull = 0.5 natural log 1+(2−1)0.8
= 1.09
1−0.8
• δ = 1.47 – 1.09 = 0.38
2
0.5k(Zα +Zβ )2
= 2 + 0.5(2)(1.645+0.842)
• n = 2 + δ 2 (k−1)
2

• n = 46 patients

(0.38) (2−1)

A sample size of 46 participants will be required for the
reliability analysis.
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